No matches
Dermatology

The Role of Type 2 Inflammation Across a Range of Pruritic Skin Diseases in Older Adults

Dr. Butler explores how type 2 inflammation is a common underlying mechanism in several prevalent chronic pruritic skin conditions affecting the elderly, such as CPUO, AD, BP, and PN
Daniel Butler
MD
Daniel Butler

Related resources

Explore the clinical presentations of bullous pemphigoid (BP), the steps for diagnosis, and the burden of disease.

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

Infographic
Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology

Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology

expert video
Disease Modification Concepts in AD

Disease Modification Concepts in AD

expert video
Barrier disruption in AD and the development of environmental and food allergies

Barrier disruption in AD and the development of environmental and food allergies

expert video
How type 2 cytokines can amplify inflammatory response in CSU

How type 2 cytokines can amplify inflammatory response in CSU

expert video
Bullous Pemphigoid Mechanism of Disease Video

Bullous Pemphigoid Mechanism of Disease Video

videoanimation
Diagnosis of Bullous Pemphigoid Interactive Patient Case

Diagnosis of Bullous Pemphigoid Interactive Patient Case

interactivity
Differential Diagnosis and Disease Onset in Older Adult Patients With AD

Differential Diagnosis and Disease Onset in Older Adult Patients With AD

expert video
Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

expert video
The Benefits of Early Intervention in AD: More Than Skin Deep

The Benefits of Early Intervention in AD: More Than Skin Deep

expert video
The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

expert video
What do we mean by disease control in AD?

What do we mean by disease control in AD?

expert video
ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

Podcast
ADVENT On Air | Exploring PN as a Distinct and Unique Disease

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

Podcast
The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

Infographic
Stepping Into Hand and Foot Dermatitis

Stepping Into Hand and Foot Dermatitis

expert video
Understanding Disease Mechanisms

Understanding Disease Mechanisms

expert video
Guideline-Based Diagnosis of Atopic Dermatitis

Guideline-Based Diagnosis of Atopic Dermatitis

interactivity
Etiology and Diagnosis of Bullous Pemphigoid

Etiology and Diagnosis of Bullous Pemphigoid

expert video
Pathophysiology of Blister Formation in Bullous Pemphigoid

Pathophysiology of Blister Formation in Bullous Pemphigoid

expert video
Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies

Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies

expert video
What We Know About Bullous Pemphigoid (BP): Challenges of the Various Clinical Manifestations, Diagnosis, and Burden for Patients and Caregiver

What We Know About Bullous Pemphigoid (BP): Challenges of the Various Clinical Manifestations, Diagnosis, and Burden for Patients and Caregivers

expert video
Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in BP

Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in Bullous Pemphigoid (BP)

expert video
ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

Podcast
Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

expert video
Scratching the Surface: Understanding Itch in Prurigo Nodularis

Scratching the Surface: Understanding Itch in Prurigo Nodularis

expert video
What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

videoanimation
Unveiling Atopic Dermatitis

Unveiling Atopic Dermatitis

expert video
Identification and Management of AD Uncontrolled With Topical Therapies in Children

Identification and Management of AD Uncontrolled With Topical Therapies in Children

expert video
Epidemiology and Pathophysiology of AD in Children

Epidemiology and Pathophysiology of AD in Children

expert video
Key Treatment Considerations for Management of Atopic Dermatitis in Children

Key Treatment Considerations for Management of Atopic Dermatitis in Children

expert video
Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

expert video
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Podcast
Chronic Spontaneous Urticaria Mechanism of Disease Animation

Chronic Spontaneous Urticaria Mechanism of Disease Animation

videoanimation
Pathophysiology of Bullous Pemphigoid

Pathophysiology of Bullous Pemphigoid

expert video
Diagnosis and Clinical Manifestations of Bullous Pemphigoid

Diagnosis and Clinical Manifestations of Bullous Pemphigoid

expert video
Unmet Needs in Bullous Pemphigoid

Unmet Needs in Bullous Pemphigoid

expert video
Heterogeneous Clinical Presentations and Diagnostic Challenges With Bullous Pemphigoid (BP)

Heterogeneous Clinical Presentations and Diagnostic Challenges With Bullous Pemphigoid (BP)

expert video
Unmet Needs and Management Challenges in Bullous Pemphigoid (BP)

Unmet Needs and Management Challenges in Bullous Pemphigoid (BP)

expert video
Under the Skin: Autoimmunity and Type 2 Inflammation in Bullous Pemphigoid (BP)

Under the Skin: Autoimmunity and Type 2 Inflammation in Bullous Pemphigoid (BP)

expert video
CSU is Associated With a High Burden and Impact on Quality of Life

CSU is Associated With a High Burden and Impact on Quality of Life

expert video
How the Understanding of PN has Evolved?

How the Understanding of PN has Evolved?

expert video
Expert Interview: Featuring Dr Shawn Kwatra on PN itch and impact on patients

Expert Interview: Featuring Dr Shawn Kwatra on PN itch and impact on patients

expert video

Learning objectives

  • Explore the central role of type 2 inflammation in driving pruritus across various inflammatory skin diseases common in older adults
Tags
patient burdenchronic pruritustype 2 inflammation
MAT-US-2603377 v1.0 - P Expiration Date: 02/18/2028

About this expert

Dermatology

Daniel Butler

MD

Assistant Dean of Student Affairs, University of Arizona College of Medicine, Tuscon, AZ

See author’s profile
Daniel Butler

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v4.0 – P Expiration Date: 10/16/2027

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region